Improved patient compliance with salmeterol/fluticasone propionate combination (SFC) compared with regular long-acting β2 agonist (LAB) and inhaled steroid (IS) therapy
T. P. McCarthy, M. S. Russell, L. Rice, S. Patel (Uxbridge, United Kingdom)
Source: Annual Congress 2002 - Asthma - Therapy and management -2
Session: Asthma - Therapy and management -2
Session type: Thematic Poster Session
Number: 409
Disease area: Airway diseases
Abstract Introduction: It is suggested that LAB/IS combination inhalers may improve compliance with asthma therapy, as only one inhaler is used for both regular therapies, and rapid clinical improvement (from the Β2 agonist component) provides a feedback system. Method: Dinlink GP prescribing data was analysed as a surrogate marker for compliance. Patient numbers and mean (standard deviation [SD]) prescriptions/year (P) for 100 practices were analysed for SFC, fluticasone propionate (FP), salmeterol (S) and beclometasone disk inhaler (BDH) (for beclometasone only BDH was evaluated, as equivalent metered dose inhalers contain >one month's medication at recommended doses). Good compliance was evaluated as collection of >=80% prescriptions/year (Price D, Thorax 1995). Results:
SFC FP S BDH No. patients 720 3073 366 2829 Mean (SD) 10.0 (5.3) 8.9 (6.5) 9.4 (5.5) 8.2 (6.1) Compliance (%) 83 74 78 68 Treatment difference (vs SFC) 1.1 0.6 1.8 95% confidence interval 0.6,1.6 0.2,1.0 1.1,2.5 p value (SFC vs comparators) <0.0001 <0.0001 =0.008
Discussion: Prescribing data are only a surrogate for compliance as patients may not use all prescriptions written for them. However, the differences between SFC and the other regular therapies prescribed were highly significant, and only SFC achieved the >=80% standard for good compliance. This study shows SFC to be associated with good patient compliance, with mean prescriptions approaching the ideal of 1/month more closely than other regular asthma medications.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. P. McCarthy, M. S. Russell, L. Rice, S. Patel (Uxbridge, United Kingdom). Improved patient compliance with salmeterol/fluticasone propionate combination (SFC) compared with regular long-acting β2 agonist (LAB) and inhaled steroid (IS) therapy. Eur Respir J 2002; 20: Suppl. 38, 409
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2 agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003
Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
EXCEL: regular maintenance therapy with salmeterol/fluticasone propionate combination (SFC) reduces exacerbations more effectively than with formoterol/budesonide combination (FBC)Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Superiority of the ‘triple‘ therapy of salmeterol/fluticasone propionate (SFC) and tiotropium (TIO) vs. individual components in COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017
Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily (OD) efficacy in asthma when dosed in the evening Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA) Source: Eur Respir J 2005; 26: Suppl. 49, 717s Year: 2005
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004